748 related articles for article (PubMed ID: 28380441)
1. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
2. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
[TBL] [Abstract][Full Text] [Related]
7. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
[TBL] [Abstract][Full Text] [Related]
11. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
12. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.
Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki C; Kikuchi M
Pathol Int; 1999 Dec; 49(12):1043-52. PubMed ID: 10632924
[TBL] [Abstract][Full Text] [Related]
13. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
[TBL] [Abstract][Full Text] [Related]
14. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma.
Fang JM; Finn WG; Hussong JW; Goolsby CL; Cubbon AR; Variakojis D
Mod Pathol; 1999 Mar; 12(3):295-300. PubMed ID: 10102615
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
[TBL] [Abstract][Full Text] [Related]
16. De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.
Kong SY; Cho EH; Woo HY; Park Q; Ko YH; Kim SH
J Korean Med Sci; 2004 Dec; 19(6):815-9. PubMed ID: 15608391
[TBL] [Abstract][Full Text] [Related]
17. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas.
Manazza AD; Bonello L; Pagano M; Chiusa L; Novero D; Stacchini A; Martini G; Vitolo U; Tarella C; Inghirami G; Palestro G; Chiarle R
Am J Clin Pathol; 2005 Aug; 124(2):182-90. PubMed ID: 16040287
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma with aberrant expression of the T-cell antigens CD2 and CD7.
Sangle NA; Agarwal AM; Smock KJ; Leavitt MO; Warnke R; Bahler D; Perkins SL
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):579-83. PubMed ID: 21836500
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
[TBL] [Abstract][Full Text] [Related]
20. Application of Immunophenotyping and Heteroduplex Polymerase Chain Reaction (hPARR) for Diagnosis of Canine Lymphomas.
Sirivisoot S; Techangamsuwan S; Tangkawattana S; Rungsipipat A
Asian Pac J Cancer Prev; 2016; 17(6):2909-16. PubMed ID: 27356711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]